Navigation Links
Preclinical study identifies 'master' proto-oncogene that regulates ovarian cancer metastasis

Scientists at The University of Texas MD Anderson Cancer Center have discovered the signaling pathway whereby a master regulator of cancer cell proteins known as Src leads to ovarian cancer progression when exposed to stress hormones. The researchers report in the current issue of Nature Communications that beta blocker drugs mitigate this effect and reduce cancer deaths by an average of 17 percent.

Src (pronounced "sarc," short for sarcoma) is a proto-oncogene a normal gene that can become an oncogene due to increased expression involved in the regulation of cell growth and division. Known to be instrumental to changes that cause normal cells to go awry, this study sheds light on its functional role as a key molecular switch affecting a downstream signaling pathway that spurs disease progression.

Led by Anil K. Sood, M.D., professor in MD Anderson's Departments of Gynecologic Oncology and Cancer Biology, researchers found that noradrenaline (NA; a stress hormone) directly affects tumor growth and spread through beta-adrenergic (ADRB) receptors expressed on tumor cells. The study demonstrated that ADRB signaling leads to Src activation via a unique protein kinase A (PKA)-mediated mechanism, which is critical to the regulation of cellular activity and cancer metastasis. This is the first time that scientists have been able to show that ADRB receptors play a direct role in Src activation by this mechanism.

"When Src is triggered by stress, it works like a dam letting out water that causes a flood downstream. Src, like the dam, is a master regulator switch that causes a chain reaction in the cells," said Sood.

Based on existing findings of Sood's ongoing work exploring potential interventions against the effects of stress, the researchers examined data on outcomes of cancer patients treated with beta blocker drugs from the U.S. Food and Drug Administration Adverse Event Reporting System. They found that mortality in patients treated with a beta blocker was reduced by an average of 17 percent across all major cancer types. Moreover, they observed a nearly 15 percent decrease in mortality among patients with ovarian and cervical cancer.

Beta blockers, also called beta-adrenergic blocking agents, treat a variety of conditions, such as heart disease, high blood pressure, glaucoma and migraines. They act on the ADRB receptors, which are also found on the heart causing the heart to beat harder and faster under stress and are involved in maintaining blood flow.

When the ADRB receptors on cancer cells are activated, they set into motion a chain of events that leads to formation of new blood vessels that feed tumor growth a process known as angiogenesis. New blood vessel formation allows tumors to grow and spread more rapidly. Beta blocking agents stop this process.

"Prior to our work, the concept of stress hormones driving cancer growth was very new and only very limited information about the effect of beta blockers on cancer outcomes in humans has been available," said Guillermo Armaiz-Pena, Ph.D., instructor of Gynecologic Oncology and Reproductive Medicine and first author of the study. "This study provides incentive to further explore beta blockers as a possible supplement to traditional cancer therapies."

A Mystery Pathway Revealed

While NA the most abundant stress hormone in the ovary has been proven to modulate multiple cellular functions important for cancer progression, how it does so had remained a puzzle. Sood's team used a multi-step process to determine how the tumor microenvironment is disrupted by stress hormones.

First, the researchers exposed ovarian cancer cells to NA and identified a number of proteins altered by stress hormones. Using bioinformatics analysis, they narrowed potential mediators to Src.

A series of subsequent experiments designed to verify the biological roles of Src in promoting ovarian cancer tumor growth in response to stress hormones revealed the signaling pathway involved in NA-mediated Src activation. Specifically, they showed:

  • PKA (also known as cAMP-dependent protein kinase) is the switch that "turns on" NA-induced Src activation;
  • The signaling pathway occurs at a particular site on the cell known as S17; and
  • This specific mechanism is key to mediating ADRB/cAMP/PKA-induced Src activation.

Building on the Stress-Cancer Connection

For the past 13 years, Sood's research efforts have focused on the effects of chronic stress on cancer metastasis. The latest study helps form a more comprehensive picture on the impact of and biological mechanics of chronic stress on ovarian cancer, as well as the role of beta blockers in slowing disease progression. Previous studies have shown:

  • Chronic stress triggers a chain of molecular events that protects breakaway ovarian cells from destruction, as heightened levels of the fight-or-flight hormones epinephrine and norepinephrine permit more malignant cells to safely leave the primary tumor a necessary step in metastasis and cancer progression.

  • When mice with ovarian cancer are stressed, their tumors grow and spread more quickly, but the effect can be blocked using propranolol, a beta blocker commonly prescribed for heart disease.

Future research will focus on other biological mechanisms that may be affected by stress. Eventually, Sood hopes his studies will help identify the cancer patients most likely to benefit from beta blockers and other stress interventions. He is also looking at the impact of stress on other diseases, such as gastrointestinal disorders.

"This is a major step forward in understanding the biology and impact of stress on cancer progression and it opens the door to study drugs that could inhibit this unique signaling pathway," Sood said.

Contact: Scott Merville
University of Texas M. D. Anderson Cancer Center

Related medicine news :

1. Genetically-engineered preclinical models predict pharmacodynamic response
2. Preclinical data support ongoing clinical trials testing IDO inhibitors as a treatment for cancer
3. BUSM study highlights attitudes toward HPV vaccination for boys
4. Study reveals 2-fold higher incidence of non-melanoma skin cancers for HIV patients
5. 1 in 5 Hospital Docs Reports Unsafe Workloads: Study
6. Coming Out Can Bring Health Benefits, Study Says
7. Study: Lungs From Heavy Smokers OK for Transplant
8. Early menopause may occur in women with BRCA gene, new study finds
9. Study demonstrates health benefits of coming out of the closet
10. No Proof Drugs Ease Kids Migraines: Study
11. Fried Foods May Boost Prostate Cancer Risk, Study Says
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of ... award to iHire in recognition of their exemplary accomplishments in worksite health promotion. , ... Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... June ... about the dangers associated with chronic pain and the benefits of holistic treatments, ... individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The ... published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone Partners ... extensive sequencing and genomics experience, as Vice President of North American Capital Sales at ... responsible for leading the sales team in the commercialization of the HTG EdgeSeq system ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... CHAPEL HILL, N.C. , June 24, 2016 ... in healthcare decisions and regulators/payers have placed more ... this new environment, patient support programs in the ... support for patients, medications. Consequently, pharmaceutical companies are ... to ensure they are providing products and services ...
(Date:6/24/2016)... June 24, 2016  Global Blood Therapeutics, Inc. (GBT) ... developing novel therapeutics for the treatment of grievous ... the closing of its previously announced underwritten public ... the public offering price of $18.75 per share. ... offered by GBT. GBT estimates net proceeds from ...
(Date:6/24/2016)... , June 24, 2016 ... Markets has announced the addition of the " ... offering. This ... and provides an updated review, including its applications in ... the total market, which includes three main industries: pharmaceutical ...
Breaking Medicine Technology: